American researchers have made a small breakthrough in cancer research: as part of a study, twelve patients were treated with the active ingredient dostarlimab – in the end, all subjects were considered cancer-free.
Dostarlimab is actually used in the treatment of uterine cancer. However, researchers at the Memorial Sloan Kettering Cancer Center in New York administered the active substance to twelve colorectal cancer patients as part of a study.
Cancer-free after just one year
For six months, the subjects had to take the drug every three weeks. The overwhelming result: Just one year after the treatment, all participants were considered cancer-free. The cancer could no longer be detected in any of the patients after six months of treatment. And that’s not all: On average, the patients did not need any further treatments for up to a year after the therapy. But despite the sensational results, the research team warns against hasty conclusions – it is still too early to assume a complete cure. The supposed miracle drug dostarlimab helps the immune system to recognize and destroy cancer cells. However, the drug was only tested on a small group of test subjects in the study. The test group is also too small to rule out side effects.
Source: Nachrichten
